By TOM MURPHY, AAMER MADHANI  and JONEL ALECCIA Associated Press WASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for the popular obesity treatments Zepbound and Wegovy. Known as GLP-1 receptor agonists, the drugs have soared in popularity in recent years,…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here